Our focus: saving, extending, and improving patients’ lives
Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to advancing science and developing treatments for orphan and hepatic diseases. RAVICTI® (glycerol phenybutyrate) Oral Liquid is our first approved product for the treatment of urea cycle disorders (UCDs). Hyperion therapeutics also markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder for UCDs and is developing glycerol phenylbutyrate for hepatic encephalopathy related to severe hepatic disease.
The THRIVE Registry
THRIVE is a long-term urea cycle disorder (UCD) patient registry that helps the scientific and medical communities advance the understanding and treatment of UCDs.
Read about the THRIVE Registry or call 1-855-UCD-2595 (1-855-823-2595).
Read about Hyperion Therapeutics in industry-related news.